Hyperion Therapeutics (HPTX) PT Lifted to $35 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr reiterated a Buy rating and raised his price target on Hyperion Therapeutics (NASDAQ: HPTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE